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Introduction
Rabies is one of the major zoonotic diseases and
still an important public health problem in devel-
oping countries. The disease is caused by rabies
virus (RV) and characterized by acute progressive
encephalitis. The envelop glycoprotein (G) of RV,
is the major antigen responsible for viral patho-
genecity and is the only target for neutralizing an-
tibodies (Dietzchold et al., 1978; Badrane and
Tordo 2001). The advances in recombinant tech-
nology had led to the development of subunit and
DNA vaccines based on rabies virus glycoprotein
(RVG) (Yelverton et al., 1983; Fu et al., 1993;
Xiang et al., 1994; Sakamoto et al., 1999; Biswas
et al., 2001; Gupta et al., 2005; Ramya et al.,
2011). The prime immune correlate of protection
in case of rabies virus infection is induction of neu-
tralizing antibodies and most of them bind to con-
formation dependant epitopes on the RVG (Ertl,
2009). Thus, purification of RVG without meddling
the conformation-dependent epitopes is necessary
to get complete protection to viral challenge.
Though, there are many chromatography method-
ologies available, purification of RVG is a cumber-
some, often unsuccessful and costly task. 
The immuno-affinity chromatography (IAC) in-
volves the immobilization of biological or synthetic
ligands to inert resin and the resulting biospecific
adsorbents will have high affinity for a single com-
pound. The IAC technique using monoclonal anti-
bodies (mAbs) are suitable for the purification of
proteins from a variety of biological substances
(Santucci et al., 1990). The recombinant proteins
intended for vaccination purpose should not con-
tain any affinity tag and thus, the IAC method can
be a suitable alternative for the purification of tag-
free recombinant RVG (rRVG) to be used as a vac-
cine candidate. Santucci et al. (1990) has reported
that IAC using antipeptide antibodies as a highly
specific and sensitive method for the purification
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Abstract
.Rabies is a disease of nervous system and causes progressive encephalitis with fatal outcome. The conformation-depen-
dent epitopes on the glycoprotein (G) of rabies virus (RV) is responsible for the induction of virus neutralizing antibodies
which is ultimately required to get complete protection from viral challenge. Therefore, a suitable chromatography technique
is necessary to purify the tag free recombinant rabies virus glycoprotein (rRVG) without altering its immunogenic epitopes.
The present study was undertaken to purify the rRVG using a conformational specific anti-rabies virus glycoprotein (RVG)
mAb, M5B4, which binds to the natively folded G. The mAb had shown a significant kinetic interaction with RVG. The
mAb immobilized onto the NHS-activated Sepharose 4 fast flow™ was used for the purification of rRVG by immuno-affinity
chromatography (IAC). The bound rRVG was eluted in IAC using 0.1M glycine with pH 2.5 and the identity of the purified
protein was confirmed by MALDI-TOF. The IAC purified rRVG induced neutralizing antibody response and 83% of the im-
munized mice were protected against intra-cerebral rabies virus challenge. The results indicate that the mAb based IAC
method can be an effective purification technique for tag free rRVG with significant level of purity, without compromising
the protein’s immunogenic potential.




In the present study, purification of the insect
cell expressed rRVG was evaluated using a RVG
site III specific mAb immobilized in an IAC. Im-
munogenicity and protective efficacy of the IAC
purified rRVG was evaluated in mice. 
Materials and methods
Cells, viruses, antibodies and animals
Vero cell derived, beta propiolactone (BPL) inac-
tivated rabies whole virus antigen (PV strain), ob-
tained from the Human Biologicals Institute;
Udhagamandalam, India was used to isolate the na-
tive RVG. The Challenge virus standard (CVS) ob-
tained from Federal Vaccine Institute; Basel,
Switzerland was used in mice challenge experi-
ment.  CVS 11 strain of RV procured from Agence
Francaise De Securite Sanitaire Des Aliments,
France and Neuro-2a cells obtained from ATCC,
USA were used in Rapid fluorescent focus inhibi-
tion test (RFFIT) to determine the neutralizing an-
tibody response. A Spodoptera frugiperda (Sf9)
cell obtained from Ingenasa, Spain was used for the
production of rRVG. RVG site III specific mAb,
M5B4 (Nagarajan et al., 2006) was used in IAC
and ELISA.
Swiss albino mice (12-15 g body weight) of
both sex, procured from National Institute of Nu-
trition (NIN), Hyderabad, India was used for as-
sessing the immunogenicity and protective
efficacy. The challenge experiments were carried
out in  Biosafety level II  at small animal testing
facility, Indian Immunologicals Limited (IIL), Hy-
derabad, India following the guidelines of Institu-
tional animal ethical committee.
Measurement of affinity constant of mAb-M5B4 by
BIAcore 
The affinity constant of  mAb (M5B4)  with Native
RVG  was measured at room temperature (23 to
25oC) using BIAcore 3000 SPR biosensor (GE,
Sweden) as described previously (Kim et al., 2003;
2006). Briefly, the carboxymethylated dextran ma-
trix (CM-5 chip) was activated with a mixture of
1-ethyl-3- (3-dimethylaminopropyl) carbodiimide
(EDC; 0.05M) and N-hydroxysuccinimide (NHS;
0.2 M). RVG was immobilized onto the activated
dextran surface using 10mM sodium acetate at pH
4-5.5 with a flow rate of 10 μl/min. The mAb
(M5B4) was diluted in PBS to final concentrations
of 2 nM, 4 nM, 6nM, 8 nM and 1µM and was in-
jected individually at a flow rate of 30 µl/minute
(Gil et al., 2002). An unrelated antigen (Yeast ex-
pressed HBsAg) was immobilized onto the control
channel under the same conditions to normalize the
instrument and buffer artifacts. The dissociation
and association rate constants were obtained by sta-
tistical analysis of the data using the BIAcore Eval-
uation software (BIAevaluation version 4.1)
provided by the manufacturer.
Preparation of immune-affinity resin
Coupling of mAb with resin
The mAb (M5B4) was immobilized onto NHS-ac-
tivated Sepharose 4 fast flow TM (GE Healthcare,
Sweden) following the procedure recommended by
manufacturer with minor modifications (Gallant et
al., 2008). Briefly, the mAb was dialysed against
coupling buffer (0.2M sodium bicarbonate, 0.5M
NaCl, pH 8.3); covalently coupled with the resin
by gentle end-to-end mixing at 25oC for 4 hours
and the coupled matrix was packed in an empty
column. The coupling efficiency (δ) was deter-
mined by an indirect method as described by Her-
nandez et al. (2001) following the formula; δ % =
χ / λ x 100, where χ is the amount of coupled pro-
tein determined as the difference between the orig-
inal amount of ligand or mAb and δ is the amount
detected in the washing fractions after coupling.
The packed column was stored at 2-8oC in 20%
ethanol until further use. 
Evaluation of ligand leakage
The amount of ligand leakage or the coupling den-
sity was measured by an antibody mediated ELISA
(Subramanian et al., 1994).  Polystyrene plates
were coated with the purified antigen from PV
strain of RV (500 ng/well) for overnight at 2-8oC.
The plate was washed and blocked with 1% bovine
gelatin in PBST and incubated at 37oC for 1 hour.
The plate was washed again and the wash fractions
from the coupled matrix (which may contain the
uncoupled mAb) was added. The plate was incu-
bated at 37oC for 2 hours and following subsequent
washing, goat anti-mouse IgG-HRPO was added.
The reaction was developed using a substrate acti-
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vated chromogen (TMB) and the colour develop-
ment was measured in an ELISA reader at 450 nm
wave length.
rRVG for Immuno-affinity purification
The rRVG was expressed in Sf9 cells and the quan-
tity of rRVG present in the soluble fraction was
measured using an immunocapture (IC)-ELISA as
described earlier (Ramya et al., 2011). Briefly, Sf9
cells were infected with the recombinant bac-
ulovirus having the RVG expression cassette at a
MOI of 4. The cells were harvested 72 hrs post in-
fection and washed thrice with PBS. The cell pellet
was lysed using the lysis buffer, formulated with
50mM Tris-HCl, 150mM NaCl, 4mM EDTA (pH
7.4), 10% DMSO and 0.6% CHAPS detergent. The
mixture was then incubated for 30 min by end-to-
end constant mixing at RT (23 to 25oC).  Finally,
the lysate was clarified, filtered and dialyzed
against PBS (pH 7.2). 
Optimization of elution buffer conditions for IAC
by ELISA
Elution buffer for the optimal recovery of bound
rRVG was determined using an ELISA method
(Santucci et al., 1990; Ibarra et al., 1999;  Ramya
et al., 2011). The microtitre plates were coated with
a known concentration of unlabelled mAb-M5B4
and incubated overnight at 2-8oC. The wells were
washed thrice with PBST and blocked for 1 hour
at 37oC using 1% (w/v) bovine gelatin in PBST.
The solubilized rRVG was added to the wells and
subjected to serial two fold dilutions. The in-house
reference standard (IRS) with known G content
was also included in the ELISA. The plate was in-
cubated for 1 hour at 37oC. The wells were washed
thrice with PBST and incubated with various elu-
tion reagents: a) 0.1M glycine-HCl, pH 2.5; b)
0.2M glycine-HCl, pH 3.5; c) 0.1M  sodium bicar-
bonate, pH 8.0 d) 8M urea, pH 7.0 and e) PBS, pH
7.0 (negative control) for 15 minutes at 37oC. The
wells were washed thrice with PBST and incubated
with the biotinylated mAb- M5B4 for 1 hour at
37oC. This was followed by the addition of strep-
tavidin-peroxidase conjugate (Sigma, USA) and in-
cubated for 1 hour at 37oC. The enzymatic color
reaction was developed using a chromogen solu-
tion and the absorbance was read in an ELISA
reader at 450 nm wave length. The bound un-eluted
RVG from various treatment groups was quantified
using a standard curve obtained for IRS (Nagarajan
et al., 2006). The amount of RVG recovered after
the buffer treatment was estimated by comparing
the bound RVG quantity in the negative control
(PBS). Buffer which had shown a higher percent-
age of recovery of the bound protein was chosen
as elution buffer for IAC (Agraz et al., 1994; Ibarra
et al., 1999).
Optimization of immuno-affinity chromatography
The cell lysate was passed through the immunoad-
sorbent matrix at a flow rate of 1 ml/minute fol-
lowed by a residence time of 30-60 minutes. The
sample was applied twice and the unbound proteins
were collected in the flow through.  The column
was washed with 5-10 column volumes of PBS at
a flow rate of 2 ml/minute. The bound rRVG was
eluted with 0.1M glycine, pH 2.5 at a flow rate of
1 ml/minute and the elutes were neutralized with
1/10th the volume of 1M Tris-HCl, pH 8.6. The
column was subsequently washed with 10 column
volumes of PBS and stored in 20% ethanol at 2-
8oC until further use (Gallent et al., 2008). 
Analysis of the immuno-affinity purified rRVG
The elution fractions from IAC were assayed for
rRVG quantity by IC-ELISA and the peak elutes
with maximum antigen content were pooled.  The
rRVG in the pooled elutes was quantified using IC-
ELISA. Purity of the protein was analyzed by SDS-
PAGE.  The ligand leakage during elution was also
analyzed by antibody mediated ELISA as described
earlier. 
Immunogenicity and protective efficacy of IAC pu-
rified rRVG
The immunogenic property of IAC purified rRVG
was analyzed in Swiss albino mice (12 to 15 g body
weight). The mice were immunized with 0.4 µg of
algel adjuvanted IAC purified rRVG by intraperi-
toneal route twice on day 0 and day 14. Mice in the
control group were inoculated with a placebo for-
mulation.
Seven days post booster immunization, the sera
were collected and RV neutralizing antibody
(RVNA) titers were determined by RFFIT (Smith
et al., 1996). Briefly, various dilutions of test and
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reference sera (Standard rabies immunoglobulin;
SRIG, NIBSC, UK) were mixed with 50 FFD50 of
CVS-11 strain of RV and incubated at 37ºC in the
presence of 5% CO2 for 90 minutes. After the in-
cubation period, Neuro-2a cells were added to the
mixture and incubated again for 20 hours at 37ºC
with 5% CO2.  The cell sheet was then fixed with
acetone and stained using anti-RV nucleocapsid
mAb conjugated with FITC (Chemicon, USA).
Based on the presence of unneutralized virus across
various dilutions, the titer was expressed as the re-
ciprocal of the dilution that neutralizes 50% of the
added virus. The antibody titers of the sample sera
were expressed as IU/ml in comparison with the
50% end point titer obtained for the NIBSC stan-
dard serum.
The protective efficacy of the purified rRVG
was analyzed by challenging the experimental mice
intracerebrally (i/c) on day 28 post immunization
with 30LD50 dose of CVS strain of RV.  Mice were
observed for the development of symptoms typical
of rabies on a daily basis for 14 days post chal-
lenge. Death of mice in the first 48 hrs post inocu-
lation was considered non-specific and those mice
were eliminated from the study. Finally, the per-




The mAb binding to the natively folded RVG at
antigenic site III (M5B4) was used in the prepara-
tion of immuno-adsorbent to purify rRVG. The
affinity constant of the mAb was evaluated using
BIAcore immunoassay and the mAb had a KD
value of 2.06 x 10-7 M, indicating a significant ki-
netic interaction with the antigen at nanomolar con-
centrations (Fig. 1).
Immuno-affinity purification of rRVG
The mAb was immobilized at a protein concentra-
tion of 10 mg/ml on NHS-activated Sepharose 4
fast flow™ at pH 8.3. The amount of uncoupled
antibody (post-coupling and blocking) and leach-
ing of the coupled mAb during the purification
process were measured using an antibody mediated
ELISA. Around 93 to 95% of the antibody was
coupled to the activated matrix and leaching of the
mAb in all column washes and elutes as measured
by ELISA was minimal. 
The elution buffer composition was chosen
from a wide range of buffers and their efficiency
was analyzed by quantifying the unrecovered
bound rRVG using an IC- ELISA. The result had
shown that 0.1M glycine (pH 2.5) and 0.2M
glycine (pH 3.5) has eluted around 80% and 40%
of the bound rRVG, respectively.  While, the 0.1M
sodium bicarbonate (pH 8.0) could elute only 10%
of the bound rRVG. The wells added with 8M urea
showed very low ELISA ODs as the urea might de-
nature the bound rRVG (Fig. 2). Ten different pu-
rification runs with varying concentration of rRVG
content were performed with three different bed
volumes of coupled gel to evaluate the consistency
in the performance. On an average, a recovery rate
of >90% was obtained with the dynamic binding
capacity of the resin being 40µg of rRVG per ml of
the coupled gel. 
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Fig. 1. Sensorgram of BIAcore assay showing kinetic bind-
ing curves of RVG with different concentrations of mAb-
M5B4 (2 nM, 4 nM, 6nM, 8 nM and 1µM) indicated by
different color. The mAb had shown an affinity constant of
2.06 x 10-7 M at equilibrium.
Fig. 2. rRVG recovery with different elution buffers as
demonstrated by IC-ELISA. The rRVG was captured on the
ELISA plates using mAb, M5B4 and various elution buffers
were tested for their ability to elute the bound antigen. Per-
centage recovery of bound rRVG was calculated based on
the reduction in rRVG quantity compared to the PBS control.
The result showed that 80% of the bound rRVG was eluted
with 0.1 M glycine (pH 2.5). The 8M urea (pH 7.0) had com-
pletely abrogated the ELISA activity due to its denaturing
property.
Analysis of the immunoaffinity purified rRVG
The eluted protein was neutralized by a suitable
buffer of alkaline pH to avoid acid-induced protein
denaturation and the specific reactivity of the neu-
tralized rRVG was verified using IC-ELISA. The
IC-ELISA results indicated that the purification
strategy has not altered the conformation of rRVG.
When the IAC purified rRVG was analyzed using
SDS-PAGE, a protein band of ~55 kDa, correspon-
ding to the size of RVG was observed (Fig. 3). The
protein band was subjected to MALDI-TOF and
the identity of protein was confirmed as the G pro-
tein of PV strain of RV. Thus, the RVG bound to
the column at neutral pH and eluted at pH 2.5.
These results are in agreement with the previous
reports (Lai, 1981; Santucci et al., 1990). 
Immunogenicity and protective efficacy of the IAC
purified rRVG
The immunogenicity of IAC purified rRVG was as-
sessed by inoculating the mice intraperitoneally on
days 0 and 14 with the immuno-affinity purified
rRVG. RVNA titers were measured from the sera
collected on day 21 post immunization and the per-
centage of mice showing more than 0.5 IU/ml
(minimum protective RFFIT titer as recommended
by WHO)  was calculated. Around 67% of mice in-
oculated with the IAC purified rRVG exhibited
protective titer on day 21 post vaccination with an
average titer of 1.46 ±1.4 (mean ± SD) and 83% of
immunized mice were protected against the intrac-
erebral challenge performed on day 28 post immu-
nization. All the unimmunized mice developed
rabies specific symptoms and died. 
Discussion
The available rabies vaccines contain inactivated
rabies virus and these vaccines are produced by
growing the virus in large scale using primary or
continuous cell lines. Therefore, very strict bio-se-
curity measures are followed in the vaccine manu-
facturing facilities. Creating and maintaining the
bio-security procedures involve huge expenditure.
Personnel working in the manufacturing facility of
cell culture based rabies vaccines are also at risk
for the infection (Winkler et al., 1973). A recombi-
nant sub-unit vaccine could be an alternative to
avoid the handling of live rabies virus in the vac-
cine manufacturing facilities. RVG alone can in-
duce neutralizing antibody response against rabies
virus and the sub-unit vaccines developed using
RVG had been found successful in inducing neu-
tralizing antibody response and protecting mice
against intra-cerebral mice challenge (Ertl, 2009;
Ramya et al., 2011). The RVG is present in trimeric
form and expressing the RVG with transmembrane
domain (TMD) is essential to maintain its trimeric
structure (Desmezieres et al., 2003). As many of
the RV neutralizing epitopes are conformation de-
pendent, the membrane extraction had to be per-
formed carefully to protect the immunogenic
property of the G.
The recombinant proteins intended for animal
or human vaccination should be devoid of any
affinity tag to meet the regulatory requirements.
Hence, a suitable method is required for the purifi-
cation of membrane bound and affinity tag free
RVG without altering its immunogenic conforma-
tion. A study was undertaken to develop an im-
muno-affinity chromatographic method for the
purification of rRVG using a mAb, M5B4, which
binds to antigenic site III of RVG. 
Affinity of the mAb to its antigen is the most
important factor to be considered while using the
mAb for the IAC. The low affinity mAbs have re-
duced binding capacity for the target antigen
whereas the high affinity mAbs require very harsh
elution conditions. Thus, mAbs with medium to
high affinity are considered as better choices for
immuno-affinity purification (Pepper, 1992; Ryu et
al., 2000). Affinity constant of 2.06 X 10-7 M was
obtained for the mAb at equilibrium, making it
suitable for IAC. An ideal elution buffer for IAC
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Fig. 3. Purification of rRVG by immunoaffinity chromatog-
raphy using mAb-M5B4 coupled with NHS-activated
Sepharose. The purified rRVG was analyzed using 12% re-
ducing SDS-PAGE and stained with silver nitrate. Lane 1-
Molecular weight marker.  Lane 2 and 3 are showing the
~55kDa band of rRVG post purification. 
should effectively release the protein without ab-
rogating the function of the protein. Among the elu-
tion buffers tested, the 0.1M glycine with pH 2.5
could elute 80% of bound proteins. The use of low
pH elution buffer does not affect the binding activ-
ity of the mAb, M5B4, when the elutes are verified
in IC-ELISA and this result is in agreement with
the earlier report (Santucci et al., 1990). 
Santucci et al. (1990) had demonstrated that the
IAC based purification of RVG using a mAb raised
against the synthetic tetrapeptide of G. This purifi-
cation strategy was found to be a very sensitive,
highly specific method for the purification of RVG
without denaturing the protein. In the present study
also, rRVG of considerable level of purity was ob-
tained, as shown in the SDS-PAGE image (Fig 3)
and the conformation of purified rRVG  was not al-
tered when checked in mAb (M5B4) based IC-
ELISA . In addition, the results of in-vivo mice
experiments have also confirmed that the immuno-
genicity of the rRVG was not altered after the pu-
rification and 83% of the immunized mice survived
the i/c challenge. The rRVG with considerable pu-
rity with the single step of IAC is considered ad-
vantageous since the single step procedure avoids
excessive handling of samples and consequent
losses. Using the mAb which binds to the trimeric
form of the protein was helpful not only for accom-
plishing the tag-free purification but also for selec-
tively enriching the immunogenic molecules from
the mixture of various forms of rRVG. 
Taken together, these results indicate that the
mAb based IAC could be a dependable technique
for the purification of RVG without altering its na-
tive conformation and the immunogenic property.
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